Dr David M. Epstein is the co-founder and president of PairX Bio, a company that specializes in the next generation of cancer selective biologics.

In this episode, David shares his experience and journey from working in various biotech companies and big pharma institutions to eventually building his own companies. One of these is Pairx Bio, a company specializing in the next generation of cancer biologics. David stresses the importance of how being able to follow the science and being transparent and open with the discussions on data collected from research projects plays a key role in the success of a company. He also touches on the success of targeted cancer therapies, some of which has led to an increase in lifespan, as well as the limitations in terms of the range of diseases that can be treated with this therapy. He also highlights the future of therapeutics in general, discussing the push in biotherapeutics and immunotherapeutics and expanding the horizon where these new innovative treatments can be effective. Lastly, he touches on the importance of how to handle IP matters and protecting one’s IP.

Host: Aakash S/O Naresh Kumar Editors: Hana Maldivita Tambrin, Dillon Chew, Jessie Wong, John Joson Ng

The show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to the team via singapore@nucleate.org.

01:01 - Introduction 05:10 - Origins of Pairx Bio and Key Characteristics For a Successful Startup 13:18 - Key differences in the process of IP patenting 18:22 - Singapore VS USA Biotech Ecosystems 20:51 - Future of Singapore’s Biotech Ecosystem